The Many Faces of Commure
Hemant Taneja’s most precious baby, throwing tantrums and drowning in toys it never deserved.
Welcome to AI Health Uncut, a brutally honest newsletter on AI, innovation, and the state of the healthcare market. If you’d like to sign up to receive issues over email, you can do so here.
Important Disclosure. This publication is written and distributed by an independent journalist. It is protected by the First Amendment to the U.S. Constitution and related principles of free expression. Those protections do not relieve me of the obligation to report accurately, and I take that obligation seriously. I strive to rely on verifiable facts, primary-source documentation, and other evidentiary material concerning companies and individuals. I also seek to present information in good faith and in a manner that is fair and non-misleading.
I am also human, and errors can occur. If a reader or an affected party identifies a specific, material factual inaccuracy, I will promptly review the underlying record. If an error is confirmed, I will correct it and, where appropriate, publish a clarification, correction, retraction, and/or apology. Disagreements over interpretation, opinion, tone, or editorial framing are not the same as factual errors. I stand by my reporting, my research, and my sources absent a demonstrated and material factual mistake.
This article was originally scheduled for publication on December 1, 2025. In connection with this report, I interviewed Commure’s President, Dan Warner. Following that interview, I provided Mr. Warner with a copy of the draft report and notice that publication was forthcoming. Mr. Warner subsequently distributed the draft within Commure, after which Commure provided written comments and proposed revisions. While I did not necessarily agree with every characterization offered, I incorporated the factual corrections provided, and extended the publication timeline by approximately three additional months to allow further response, after the company objected to what it described as a “short timeframe for review.” However, no additional information was provided after that point. This version reflects the incorporation of those original corrections and is narrower and less critical than my initial draft as a result.
Since my initial draft, I have updated the revenue multiples chart and added a section addressing KLAS ratings, which Commure frequently cites. That discussion is presented as analysis and commentary based on publicly available information and other verifiable sources, and reflects my evidence-based opinion regarding KLAS Research and the relevance of its ratings.
I also added a section regarding Commure’s acquisition of Memora Health, as I believe there may have been potential conflicts of interest. It may also serve as an instructive example of how venture capital firms often structure transactions, particularly in healthcare, to maximize their returns, at times to the detriment of other parties.
I also removed the section concerning investors’ due diligence and fiduciary obligations when investing in ventures such as General Catalyst, as that issue is not directly related to Commure.
And I removed the screenshot of the negative Glassdoor review, partly because Commure identified inaccuracies in it, and primarily because I believe I have sufficient material from my own research.
Apart from those changes, the edits made since the first draft have been limited and largely non-substantive. Most edits involved clarifying wording and removing or narrowing statements that could be read as unnecessarily contentious or ambiguous, without changing the core factual basis of the reporting.
I also reiterate an important distinction that applies to this and similar reporting. Any criticism expressed herein is directed at the company, its products, and its public-facing conduct or claims. It is not intended to disparage the company’s employees as individuals. Many good and well-intentioned people work at Commure and at other organizations I report on. I have interacted with some of them directly and have respect for their professionalism, regardless of any disagreement with corporate strategy, marketing, or product representations.
I also wish to clarify that, although I have concerns regarding certain matters occurring at Commure, I am not asserting that any unlawful conduct has taken place.
Going forward, I encourage Commure and any other parties who are the subject of my reporting to engage respectfully and in good faith with the journalistic process. I am committed to resolving legitimate factual disputes through evidence-based dialogue. If credible, specific corrections are presented, I will address them directly.
Finally, readers should note that this publication may use pointed, vivid, or otherwise colorful language. That is an element of journalistic style and protected commentary. Even so, I regret any offense caused by phrasing that distracts from the substance. The purpose of this work is to pursue the truth. In a period marked by significant AI hype, particularly in healthcare, where many products are marketed as “the next great thing,” rigorous scrutiny and evidence-based reporting are necessary. I genuinely aim to provide that scrutiny, and based on reader feedback, I believe it serves a useful function for the industry.
🚨 And a quick announcement:
As you are well aware, these research and investigations are time- and labor-intensive. I’m a one-man operation. My Founding Members Club of (currently) 19 is what I heavily rely on for resources to conduct these kinds of thorough investigations. If you’d like to become a Founding Member of the AI Health Uncut community, you can join through this link. (Substack may ask you to enter your email first before taking you to the payment page.) You’ll be making a real impact, helping me continue to challenge the system and push for better outcomes in healthcare through AI, technology, policy, and beyond.
My readers already know I took a hard look at Hippocratic AI in a three-part deep investigation (here, here, and here), exposing a failing Hemant Taneja portfolio company and the atrocities and alleged lies happening inside Hippocratic AI.
It turns out this may be a pattern across Hemant’s portfolio companies.
Next up is Commure, the golden child and absolute personal favorite of Hemant Taneja, CEO of General Catalyst and the de facto boss of the healthcare VC mafia, as I affectionately call him. (Still, I have no idea why Hemant blocked me on LinkedIn. I hope there are no hard feelings. 😉)
🚨 Another quick announcement:
I will be speaking at the Digital Health and AI Innovation Summit (DHAI) 2026 in Boston on June 8-9. Register here. I’ll be talking about my newly developed methodology for measuring VC skill in picking “generational companies.” It’s based on a unique dataset of around 200 publicly traded health tech companies and around 2,000 investment firms and individuals that invested in them. It’s a massive dataset I tediously built over the past several months. And unlike the Forbes annual ranking, I’m using performance metrics, not some subjective “perception of greatness.” 😉 I’ll explain more about this dataset in future posts. I also plan to offer free access to it for my Founding Members.
Alright, back to Commure…
While Commure has been failing the medical community, it will never actually fail because it keeps getting propped up by massive cash infusions from General Catalyst and every other VC bro shop Hemant is tied into. Translation: basically the whole Silicon Valley ecosystem.
Many people in healthcare don’t even know what Commure does. Supposedly it “builds software that makes physicians’ lives easier” 🤷♂️. But here’s the kicker – it doesn’t matter. No matter what Commure does, the cash will never stop.
Commure might be the weirdest startup in healthcare, according to Business Insider. Allegedly, the company did not respond to media questions, and the information in Business Insider’s investigation came primarily from employees. Interestingly, employees were under obligations not to speak to the media but did so anyway because the internal situation was “ridiculous.”
Commure, the so-called $6B “platform” company, has raised approximately $1.014B across 13 rounds, including merger-related equity. (Source: CBInsights.) (It is still, amazingly, short of Ali Parsa and Babylon’s $1.5B total fundraise of someone else’s money that fairly quickly evaporated into dust.) Commure has cycled through four CEOs in five years and pivoted from its original mission. Yet somehow, it survives. In fact, on paper it even thrives. Why? Because its co-founder and chief backer, Hemant Taneja, has given it a blank check. Taneja has a colossal vision for Commure and, as one former exec put it, “Taneja will not, under any circumstances, allow Commure to fail.” This sounds to me like Commure is TCF: Too Corrupt to Fail.
Backed by General Catalyst’s seemingly infinite cash and crony connections, Commure has been Hemant Taneja’s baby. It has become a black hole for investor money and a harbor for shady deals like Memora Health, where, shockingly, General Catalyst was on both sides of the trade in a potential conflict of interest. It is a case study in how hype and hubris can trump reality in healthcare tech.
TL;DR:
1. Hemant Taneja: The Godfather of Hype and Hypocrisy
2. The Myth of “AI-First”
3. Toxic Culture and Talent Exodus
4. Too Corrupt to Fail? Commure’s (Multi-)Billion-Dollar Safety Net
5. When You Can’t Innovate and You Have Infinite Cash. What Do You Do? Buy. Buy. Buy.
6. Was the Memora Deal a Conflict of Interest?
7. Why KLAS Ratings May Be the Wrong Benchmark for Healthcare IT Products
8. Good People Inside Commure — Interview with Dan Warner, President of Commure
9. Conclusion: Commure May Be Failing, But Plenty of Good People Still Work There
I want to acknowledge the brave individuals who spoke with me, both anonymously and openly, about what’s happening inside Commure. We need more people like them. Silence isn’t neutrality. It’s complicity.
Alright, let’s unravel this mess…
